Crimson Publishers Publish With Us Reprints e-Books Video articles

Abstract

Surgical Medicine Open Access Journal

Same Story with Different Endings in HER2- Positive Breast Cancer: Why the Benefit of Pertuzumab is Robust in the Metastatic Scenario and Modest in the Adjuvant Setting?

Submission: December 20, 2019;Published: January 08, 2020

DOI: 10.31031/SMOAJ.2019.03.000560

ISSN : 2578-0379
Volume3 Issue2

Abstract

While the incorporation of pertuzumab to a chemotherapy and trastuzumab backbone (dual HER2 blockade) yielded a robust improvement in the outcomes of HER2-positive metastatic patients in the CLEOPATRA study, in the adjuvant setting the same magnitude of benefit was not reproduced with the addition of pertuzumab in the overall population of the APHINITY study, being the reasons for this discrepancy unknown so far. In the present manuscript, we discuss biological and clinical differences between metastatic and early-stage HER2-positive breast cancer that may potentially explain the different magnitudes of benefit observed with pertuzumab in the different disease settings.

Keywords: Breast cancer; HER2; Pertuzumab

Get access to the full text of this article